Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in peritubular myoid cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 373 | 0.85 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
Knock down and overexpress WNT2B in microglia; measure LRRK2 kinase activity (pT73-Rab10) and lysosome position and uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release).
- Cell type
- microglia
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- LRRK2 kinase activity (pT73-Rab10) and lysosome position
- Functional readout
- uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release)
- Rule-out
- If neither arm moves LRRK2 kinase activity (pT73-Rab10) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of WNT2B in iPSC-derived microglia (iMGL); n = 3 differentiations; readouts: LRRK2 kinase activity (pT73-Rab10) and lysosome position; uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release). Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- WNT2B in microglia, braak+0.39 (p 0.299) → +0.11 (p 0.779)receipt 16656
- WNT2B in dopamine neurons, braak-0.18 (p 0.639) → -0.71 (p 0.031)receipt 16657
Swarm cases
receipt 16657: WNT2B in dopamine neurons, braak
- power
- full sample -0.49 (p 0.039, n 18), 95% CI -0.78 to -0.03. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.52 (p 0.026, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.038, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.42, sign flips 0; without severely affected donors -0.49 (p 0.039, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for WNT2B in dopamine neurons.
case closed: nothing better to follow up.
receipt 16656: WNT2B in microglia, braak
- power
- full sample +0.21 (p 0.403, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.18 (p 0.476, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.18 (p 0.476, n 18). could be the mix.
- skeptic
- leave-one-out range +0.11 to +0.40, sign flips 0; without severely affected donors +0.21 (p 0.403, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for WNT2B in microglia.
case closed: nothing better to follow up.
Receipts
loading the receipts